[Federal Register Volume 80, Number 142 (Friday, July 24, 2015)]
[Notices]
[Pages 44139-44140]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-18101]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Bispecific Chimeric Antigen Receptors to CD22 and CD19 for Treating
Hematological Cancers
Description of Technology: Chimeric antigen receptors (CARs) are
hybrid proteins that have antibody binding fragments fused to protein
signaling domains that activate T cells. The antibody binding fragments
allow the CAR to recognize specific cell types, thereby activating the
T cell through the protein signalling domain. Once activated, the T
cells selectively eliminate the cells which they recognize. By
engineering a T cell to express CARs with antibody binding fragments
which are specific for cell surface proteins that are associated with
diseased cells, it is possible to treat the disease. This is a
promising new therapeutic approach known as adoptive cell therapy.
CD22 and CD19 are cell surface proteins that are expressed on a
large number of B cell lineage hematological cancers, such as leukemia
and lymphoma. CD19 CAR T cells have demonstrated potent activity
against leukemia in early clinical trials. However, some of these
patients will relapse with leukemia that no longer expresses the CD19
protein. This technology concerns the use of two high affinity antibody
binding fragments as the targeting moieties of a CAR: One to CD22
(m971), and one against CD19 (FMC63). The resulting CAR can be used in
adoptive cell therapy treatment for cancers which express either CD22
or CD19.
Potential Commercial Applications:
Treatment of diseases associated with increased or
preferential expression of CD22 or CD19.
Specific diseases include hematological cancers such as
chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) acute
lymphoblastic leukemia (ALL) and lymphoma.
Competitive Advantages:
High affinity of the m971 and FMC63 antibody binding
fragments increases the likelihood of successful targeting.
Targeted two antigens expressed on the same type of
diseased cells may increase efficacy relative to targeting a single
antigen.
Targeted therapy decreases non-specific killing of
healthy, essential cells, resulting in fewer non-specific side-effects
and healthier patients.
Hematological cancers are susceptible to cytotoxic T cells
because they are present in the bloodstream.
Development Stage:
In vitro data available.
In vivo data available (animal).
Inventors: Terry J. Fry, et al. (NCI).
Publications:
1. Haso W, et al. Anti-CD22-chimeric antigen receptors targeting B-
cell precursor acute lymphoblastic leukemia. Blood. 2013 Feb
14;121(7):1165-74. [PMID 23243285]
2. Lee DW, et al. T cells expressing CD19 chimeric antigen receptors
for acute lymphoblastic leukaemia in children and young adults: a
phase 1 dose-escalation trial. Lancet. 2015 Feb7;385(9967):517-
[[Page 44140]]
28. [PMID 25319501]
Intellectual Property: HHS Reference No. E-106-2015/0-US-01--US
Provisional Application No. 62/135,442 filed March 19, 2015.
Related Technologies:
HHS Reference No. E-080-2008/0-US-03--US Patent
Application No. 12/934,214 filed September 23, 2010.
HHS Reference No. E-291-2012/0-PCT-02--PCT Application No.
PCT/US2013/060332 filed September 18, 2013.
Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632;
[email protected].
Magnetic Resonance Magnification Imaging
Description of Technology: With conventional MRI, it is inherently
time-consuming to generate high dimensional images with high spatial
resolution. This invention, inspired by optical magnification, uses a
fundamentally different approach to MRI image formation. It uses
specially designed radiofrequency pulses to interact with the magnetic
field gradient, wherein the region of interest is filled with more
pixels resulting in increased spatial resolution and reduced overall
scan times for patients at the region of interest. Currently, 3-fold
magnification has been achieved in vivo. This invention allows the
magnification of predefined regions of interest and improved diagnostic
images for the same scan time.
Potential Commercial Applications:
Diagnostic imaging.
Environmental Sampling/Testing.
Quality Control/Quality Assurance.
Competitive Advantages:
Magnified image with increased image resolution.
A 3-fold increase in spatial resolution in vivo in
comparison to traditional MRI scans.
Reduced scan time.
Patient friendly--with reduced scan time, there is less
patient discomfort especially for those who experience claustrophobia.
Development Stage:
Early-stage.
In vivo data available (animal).
Inventor: Jun Shen (NIMH).
Intellectual Property: HHS Reference No. E-252-2014/0--US
Provisional Application No. 62/059,520 filed October 3, 2014.
Licensing Contact: Jennifer Wong, M.S.; 301-435-4633;
[email protected].
Collaborative Research Opportunity: The National Institute of
Mental Health is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate or commercialize Magnetic Resonance Magnification Imaging. For
collaboration opportunities, please contact Jun Shen at
[email protected] or 301-451-3408.
Dated: July 20, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-18101 Filed 7-23-15; 8:45 am]
BILLING CODE 4140-01-P